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In October 2007, an epidemic of hepatitis E was sus-
pected in Kitgum District of northern Uganda where no 
previous epidemics had been documented. This outbreak 
has progressed to become one of the largest hepatitis E 
outbreaks in the world. By June 2009, the epidemic had 
caused illness in >10,196 persons and 160 deaths.
H
epatitis E virus (HEV) infection causes large epidem-
ics of liver disease in developing countries (1–3). In 
epidemic settings, HEV is transmitted by the fecal–oral 
route, and the most commonly attributed source of infec-
tion is feces-contaminated drinking water (4). The incuba-
tion period after exposure ranges from 3 to 8 weeks (mean 
40 days) and is dose dependent (5,6). Illness is generally 
self-limited, with death rates <4% in the general population 
(7), but a strikingly high death rate (10%–25%) has been 
reported among pregnant women (8).
In October 2007, an epidemic of hepatitis E was sus-
pected in northern Uganda, where no previous epidemics 
had been documented. However, outbreaks of hepatitis 
E had occurred in neighboring Sudan and Chad in 2004 
(9,10). Beginning in the Madi Opei subcounty of Kitgum 
District, this outbreak has progressed to become one of the 
largest hepatitis E outbreaks in Africa and globally. By June 
2009, a year after the study we report here, the epidemic 
involved all 19 subcounties of Kitgum and had caused ill-
ness in >10,196 persons and 160 deaths (local surveillance, 
unpub. data). This report describes the results of a case 
ﬁ  nding and seroprevalence survey in 2 subcounties of Kit-
gum District, Madi Opei and Paloga.
The Study
Two subcounties, Madi Opei and Paloga, were select-
ed for a census and seroprevalence survey. In June 2008 
(at the time of this investigation), the 2 subcounties repre-
sented different stages of the epidemic: Madi Opei was the 
ﬁ  rst subcounty to experience the epidemic; the epidemic 
appeared to affect Paloga relatively later. No differences 
in demographic and socioeconomic characteristics were 
evident between the residents of the 2 subcounties. Trained 
village health team members conducted a hut-to-hut cen-
sus. The census was completed using a standardized data 
collection instrument. Histories of jaundice and jaundice-
related death were also obtained.
For the seroprevalence survey, a random sample of res-
idents was identiﬁ  ed from the list created during the census. 
Persons who consented to participate had blood collected 
by venipuncture. Blood specimens were tested for immu-
noglobulin (Ig) M and IgG against HEV (MP Biomedi-
cals Asia Paciﬁ  c Pte Ltd, Singapore), HEV RNA (by an 
in-house reverse transcription–PCR assay), and serologic 
markers of infection by hepatitis A virus, hepatitis B virus, 
and hepatitis C virus. A subset was analyzed to determine 
the HEV genotype. The HEV sequence from this outbreak 
strain was compared with other HEV genotype 1 strains 
isolated from past epidemics. Because the 2 sites were in 
different stages of the outbreak as determined by the differ-
ent durations and peaks of the epidemic at the time of the 
investigation (June 2008), HEV attack and death rates were 
calculated separately by site and in aggregate. All statisti-
cal analyses were performed with SAS version 9.1 (SAS 
Institute, Inc., Cary, NC, USA).
A total of 19,098 persons were counted in Madi Opei 
(10,535) and Paloga (8,563) during the census. In Madi 
Opei, there were 2,137 families and an average of 4.9 
persons per household. In Paloga, there were 1,884 fami-
lies and an average of 4.5 persons per household. Figure 
1 shows the distribution of cases of jaundice in Kitgum 
District, by week of report, October 2007 through Janu-
ary 2009 (data from facility-based passive surveillance). 
The overall symptomatic hepatitis E attack rate, based on 
hut-to-hut case ﬁ  nding, in the 2 subcounties was 25.1%. 
However, at the time of the investigation, the epidemic 
had peaked (Figure 2, panel A) in Madi Opei and was 
still increasing in Paloga: 30.1% of Madi Opei residents 
reported jaundice, but only 18.9% of Paloga residents re-
ported jaundice by the time of the investigation. Symp-
tomatic cases reached their height in April 2008 in Madi 
Opei but did not peak in Paloga until June 2008 (Figure 
2, panel B).
Of the 10,535 Madi Opei residents, jaundice was 
reported by 3,170 (30.1%). In Paloga, jaundice was re-
ported by 1,619 (18.9%) of 8,563 residents. The number 
of symptomatic cases was higher for women (28%) than 
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for men (22%; p<0.001) (Table). The symptomatic attack 
rate was lowest for children <2 years of age (6.9%) and 
highest for pregnant women (80.7%). In the 2 subcoun-
ties, 72 deaths were reported among 4,789 persons with 
jaundice, yielding an estimated case-fatality rate among 
jaundice cases of 1.5%. Among the 72 jaundice-related 
deaths, a disproportionate number occurred in children 
<2 years of age (12/92, 13%) and in pregnant women 
(13/189, 6.9%).
Sixty-six percent of 720 randomly selected residents 
agreed to participate in the survey and blood draw. Of the 
total tested, 305 (64.4%) were positive for IgM or IgG 
against HEV or both. In a subset of 142 specimens select-
ed at random from among the participants of the survey 
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Figure 1. Distribution of cases of jaundice during an epidemic of hepatitis E in Kitgum District, Uganda (N = 7,919), by week of report, 
October 2007 through January 2009.
Figure 2. Distribution of cases of jaundice during an epidemic of hepatitis E in A) Madi Opei subcounty (n = 1,026) and B) Paloga 
subcounty (n = 1,248), by week of report, Kitgum District, Uganda, October 2007 through January 2009. Data are from facility-based 
passive surveillance.and tested by reverse transcription–PCR, 24 were found to 
be positive for HEV RNA. Subsequent sequence analysis 
showed that HEV found in all 24 specimens belonged to 
genotype 1. There was close resemblance of the open read-
ing frame 2 gene of the HEV genotype 1 isolates from this 
and the Chad outbreak. Other causes of viral hepatitis were 
rare. Of 469 persons tested, only 12 (2.5%) tested positive 
for IgM to hepatitis A virus, 3 (0.6%) were positive for IgM 
to hepatitis B core antigen, and 4 (0.8%) were positive for 
antibody to hepatitis C virus.
Conclusions
The symptomatic HEV attack rate and HEV-related 
deaths observed in this epidemic were high. Given that out-
breaks of hepatitis E had not been observed or reported in 
Uganda previously, a lack of preexisting immunity from 
prior exposure in this population may well have facilitated 
the outbreak. Nevertheless, outbreaks had been reported 
in neighboring countries and, although there were no se-
quences available from the epidemic in southern Sudan, 
phylogenetic-relatedness analysis showed close resem-
blance of the outbreak strain to the strain from the Chad 
outbreak. There was no clear epidemiologic link of this 
outbreak to the neighboring countries.
Women in this epidemic were substantially affected, 
and, as seen in previous epidemics, pregnant women are 
particularly at increased risk of death (4). Furthermore, our 
survey also showed that children (0–2 years of age) were at 
a higher risk of dying from hepatitis E, despite the fact they 
were generally asymptomatic. This ﬁ  nding corroborates a 
similar observation for a hepatitis E epidemic in the for-
mer Soviet Union in 1985–1987 (11). We do not know why 
pregnant women and young children were at increased risk 
for death from this infection, but there may be gender- or 
age-speciﬁ  c risk for exposure or differential susceptibility 
to infection (1,7).
This investigation has some limitations. For the cen-
sus, the clinical diagnosis of hepatitis E was by self-report 
only, and the death rate data were based on verbal autopsy. 
Jaundice could have been overdiagnosed for young chil-
dren and thus could have contributed to a skewed death rate 
being reported for this group.
Current understanding of HEV transmission indicates 
that effective prevention and control depend on ensuring a 
safe drinking water supply, adequate sanitation, and proper 
personal and environmental hygiene. However, due to the 
rapid transmission of HEV and the long incubation period of 
this disease, it is difﬁ  cult to mount adequate prevention mea-
sures in a timely manner. This difﬁ  culty was evident in the 
long duration of the outbreak in Kitgum district. Therefore, 
we recommend that increased priority be given to develop-
ing a promising current hepatitis E vaccine candidate as soon 
as possible (12). Availability of vaccine is also needed in 
light of the high death rate of children and pregnant women. 
However, the safety of such a vaccine for pregnant women 
needs to be determined before use in this population.
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